The tariff skips the cheap pills. The shortages don't.
America now taxes the ingredients of new patented drugs at 100%. Ingredients for everyday generics pay nothing for now. Medicines still run short.
vizmaya desk · 9 October 2026
A pill is two things: the part that heals, and everything else.
No API, no pill. That is why a short supply of one ingredient can empty a pharmacy shelf.
Four numbers hold the whole story.
medicines are short in the US right now
of this year's new shortages are medicines with a single maker
on patented drugs and their ingredients
on imported generics, until August 2028
Sources: ASHP Q2 2026 shortages report; law-firm summaries of the 2 April 2026 Section 232 proclamation; The Pharma Letter and two other outlets on the July announcement.
Two places make most of the ingredients in America's prescriptions.
India and the European Union together make more than half of the active ingredients, by volume, in prescription medicines sold in the US. The EU alone supplies 43% of the ingredients in branded medicines.
Source: USP Medicine Supply Map, 2025.
India makes the medicine, but buys much of its ingredients from China.
For 11 of these 12 ingredient lines, China supplied more than three quarters of what India imported in 2024-25.
InterpretationSo a pill made in India can still depend on a Chinese ingredient.
Source: PIB, 10 March 2026 (DGCI&S customs data), 12 lines from the annexure. This measures India's imports, not US imports.
In one year, China's share of India's penicillin imports jumped 16 points.
It went from 77% to 93%. Most other lines barely moved. Steroid hormones went the other way, down about 9 points.
Source: PIB, 10 March 2026, annexure by HS code. Change = 2024-25 share minus 2023-24 share.
Shortages are climbing again, though they are still below the peak.
Active shortages in the US have now risen three quarters in a row.
Source: ASHP drug shortages report, Q2 2026. We show two points, not a trend line, because the other quarters came from news coverage, not ASHP's own file.
Nearly half of this year's new shortages are medicines with only one maker.
When one company makes a drug, one bad inspection or one broken line can empty the shelf. Ifosfamide, a chemotherapy drug, is in severe shortage this year after a key supplier had quality problems.
Source: ASHP drug shortages report, Q2 2026 (new 2026 shortages that are sole-source products).
The 100% tariff hits new patented drugs and skips the cheap ones.
Patented drugs and their ingredients. In force since 31 July 2026 for 17 named firms and 29 September 2026 for everyone else.
Generics, biosimilars, orphan drugs, and ingredients on the US Strategic API Reserve list.
Deals lower the rate: 15% for the EU, Japan, South Korea and Switzerland, and 0% under pricing deals until 20 January 2029. Source: law-firm summaries of the 2 April 2026 proclamation (Amundsen Davis, JD Supra, DCAT).
Generics are next, but not for two years.
This was announced on 21 to 22 July 2026 and reported by three outlets. We could not confirm that a signed order exists yet. Sources: The Pharma Letter, INDmoney, PharmaNow.
So who pays? Not the importers, not yet.
- FactThe tariff skips generic ingredients until August 2028, and 48% of new shortages are one-maker drugs.
- InterpretationSo today the bill arrives as missing medicine for patients and extra hunting for substitutes by pharmacy staff.
- SpeculationIf generics are taxed from 2028, importers pay first. Some of that may reach US buyers. No source we found puts a price on it.
A thin week: one real event, plus its backdrop.
- 6 OCT 2026A US nonprofit, the API Innovation Center, launched a "fragility index". It scored 400+ medicines. It rates 14 as Severe and 71 as High, about one in five. The scores are its own and its method is not yet published.
- 29 SEP 2026, 10 DAYS AGOThe 100% tariff on patented drugs took effect for all remaining companies.
- 9 OCT 2026An analyst note says Indian generic makers are looking beyond the US. It is commentary, not a new event.
Sources: API Innovation Center release (GlobeNewswire, 6 Oct 2026); Section 232 summaries; GlobalData via AZoLifeSciences.
What could make this story wrong.
- Firms do pay. Big companies avoided the 100% tariff only by signing price and onshoring deals, and those deals cost money.
- The fragility index comes from a group that argues for making ingredients in the US. Nobody outside it can check the scores yet.
- Shortages are well under the 2024 peak: 227 now, 323 then.
- Our China figures measure India's imports, not America's. They are a stand-in for the chain, not the whole chain.
Four dates and one document to watch.
- 31 JUL 2028The announced end of the 0% window for imported generics.
- 20 JAN 2029Tariff exemptions under pricing deals run out.
- 2 APR 2030The 20% onshoring-plan rate rises to 100%.
- NO DATE YETThe full fragility index report, and any signed order on the generics tariff.
20 claims checked. 11 verified, 2 contested, 7 left off the page.
Contested: India's total API import bill (sources disagree) and the size of the API market (vendor estimates range from $149B to $266B for 2026). Neither is used.
Unverified and not used: the fragility index's drug-level scores, FDA inspection rates by country, India's Q1 export figures, and whether the generics tariff is signed.
Not found: US API imports by source country from customs data, FDA drug master files by country, and any FDA or CDSCO action inside 2 to 9 October. A trend chart was not drawn because only one series, the PIB annexure, had 8 or more primary points.
PIB, APIs imports from China, 10 Mar 2026
ASHP drug shortages report, Q2 2026
Amundsen Davis, Section 232 alert
vizmaya desk · 9 October 2026 · Spin 4768c7c7 · No photos used: image sources were not reachable from this build.